Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
An Alternative for Those Who Can’t Receive Docetaxel?
Breast Cancer Res; 2016 Dec 13; Perez, et al
The combination of vinorelbine, pertuzumab, and trastuzumab was active and reasonably well tolerated in a multicenter, two-cohort, open-label study involving 106 individuals.
Participants had HER2-positive locally advanced or metastatic breast cancer and had received neither chemotherapy nor biological therapy previously. They were given pertuzumab (840 mg loading, 420 mg maintenance doses) and trastuzumab (8 mg/kg loading, 6 mg/kg maintenance doses) weekly for 3 weeks, followed by vinorelbine (25 mg/m2 initial dose, 30-35 mg/m2 maintenance doses) on days 1 and 8 or 2 and 9 of each cycle. Among the results:
- Objective response rate was 74.2%.
- Median progression-free survival was ~14 months.
- Serious adverse events occurred in 3 in every 10 participants.
- 17% experienced adverse events suggestive of congestive heart failure, yet there were no confirmed cases.
The authors concluded that the regimen offers a potential alternative for patients who cannot receive docetaxel for first-line treatment of HER2-positive locally advanced metastatic breast cancer.
Perez E, López-Vega J, Petit T, et al. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Res. 2016;18(1):126. doi:10.1186/s13058-016-0773-6.